Stevanato Group S.p.A.

NYSE:STVN

Medical - Instruments & Supplies

Healthcare
$15.36 +3.90%

+$0.67 today

Market cap
$4.20B
Beta
0.78
P/E (TTM)
29.9
EPS (TTM)
$0.52
Dividend yield
0.35%
52W Low $12.89High $28.00

Volume 0.61M

Average 0.52M

STVN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Stevanato Group S.p.A.NYSE: STVN

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development grows, but more slowly than its trailing trend

Q2 FY2026 research & development of €6.2M rose 2.6% year over year, behind the +5.3% change in trailing-twelve-month research & development. Sequentially, it rose 6.1% from the prior quarter. Over 3 fiscal years it compounded at -10.8% a year.

Context

  • Research & development amounted to 2.1% of revenue in FY2025, down 0.7 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +2.6% toward the trailing-twelve-month pace of +5.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
€6.2M+6.1% QoQ
Last fiscal yearDec 2025
€24.4M-23.0% YoY
LTMJun 2026
€25.44M+5.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.6%——
1 year-23.0%——
3-year CAGR-10.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

EUR · from the income statement

Latest · FY2025
24.4M EUR
Year-over-year change
-23.0%
4-year CAGR
-4.7%

Research & Development vs competitors

How STVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +5.3% is the 4th highest of 7, against a peer median of +6.8%.
  • Research & development amounts to 2.1% of revenue for STVN, versus a peer median of 7.5%.
STVN Competitors
Research & Development for STVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$404M USD+12.5%+6.5%7.6%
ATRAptarGroup, Inc.LTM Jun 2026$325.34M USD——8.3%
NUVLNuvalent, Inc.LTM Mar 2026$316.16M USD+24.7%+68.9%—
TFXTeleflex IncorporatedLTM Jun 2026$195.47M USD+23.6%-2.0%7.5%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$187.86M USD-3.5%+46.8%24.2%
MASIMasimo CorporationLTM Apr 2026$122.5M USD-38.4%-12.9%7.9%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$96.93M USD+1.0%+8.8%6.0%
STVNStevanato Group S.p.A.LTM Jun 2026€25.44M EUR+5.3%-10.8%2.1%
BTSGBrightSpring Health Services, Inc. Common StockLTM Sep 2026$0 USD——0.0%
AVTRAvantor, Inc.LTM Jun 2026$0 USD——0.0%
CHEChemed CorporationLTM Jun 2026$0 USD——0.0%
Peer median (excluding STVN) —+6.8%+7.7%7.5%

Competitors are the stored peer set for STVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue843.92M983.68M1.09B1.1B1.14B
Cost of Revenue578.52M663.88M745.46M801.72M809.15M
Gross Profit265.41M319.8M339.89M302.32M330.33M
Gross Margin31.4%32.5%31.3%27.4%29.0%
Research & Development29.62M34.39M35.67M31.67M24.4M
Selling, General & Admin82.95M111.83M113.92M118.6M122.85M
Operating Expenses103.18M127.37M139.17M141.18M147.25M
Depreciation & Amortization56.38M64.82M78.48M80.65M88.57M
EBITDA226.93M256.4M272.35M247.8M292.01M
EBITDA Margin26.9%26.1%25.1%22.4%25.6%
Operating Income162.23M192.43M200.72M161.14M183.08M
Operating Margin19.2%19.6%18.5%14.6%16.1%
Interest Income548K648K792K1.72M12.49M
Interest Expense4.87M3.94M4.32M6.86M21.8M
Other Income / Expenses3.45M(4.79M)(11.17M)(854K)(1.44M)
Income Before Tax165.67M187.64M189.55M160.29M181.64M
Pre-Tax Margin19.6%19.1%17.5%14.5%15.9%
Income Tax Expense31.4M44.63M43.86M42.52M47.35M
Net Income134.32M142.85M145.63M117.78M134.28M
Net Margin15.9%14.5%13.4%10.7%11.8%
EPS (Basic)0.530.530.550.430.49
EPS (Diluted)0.530.530.550.430.49
Weighted Avg Shares264.7M264.7M264.95M272.87M273M
Weighted Avg Shares (Diluted)264.7M264.7M264.98M272.88M273M

Stevanato Group S.p.A.

NYSE:STVN

Intrinsic Alpha fair value

Locked

Current Price

$15.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.